NYSEAMERICAN:IBIO iBio (IBIO) Stock Price, News & Analysis $0.92 +0.07 (+8.50%) As of 04/25/2025 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsHeadlinesSEC FilingsShort InterestBuy This Stock About iBio Stock (NYSEAMERICAN:IBIO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get iBio alerts:Sign Up Key Stats Today's Range$0.81▼$0.9350-Day Range$0.70▼$6.4152-Week Range$0.64▼$6.89Volume520,218 shsAverage Volume686,663 shsMarket Capitalization$3.20 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewiBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cancer, and other diseases. The company's technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein. Its product pipelines for cardiometabolic disease area include IBIO-101, an anti-CD25 Mab that binds and depletes immunosuppressive regulatory treg cells to inhibit the growth of solid tumors; CCR8, an antibody that enhance the body's immune response against cancer cells; and trophoblast cell surface antigen 2, a monoclonal antibodies, as well as MUC16 and Target 5 antibodies. In addition, the company is developing EGFRvIII, an antibody therapeutics that targets EGFRvIII protein with the aim to address these cancer types without affecting healthy cells. It has a collaboration agreement with AstralBio to discover and develop novel antibodies for obesity and other cardiometabolic diseases. iBio, Inc. was incorporated in 2008 and is headquartered in San Diego, California.Read More… iBio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks7th Percentile Overall ScoreIBIO MarketRank™: iBio scored higher than 7% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for iBio. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioiBio has a P/B Ratio of 0.06. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about iBio's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted9.94% of the float of iBio has been sold short.Short Interest Ratio / Days to CoveriBio has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in iBio has recently decreased by 20.90%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldiBio does not currently pay a dividend.Dividend GrowthiBio does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted9.94% of the float of iBio has been sold short.Short Interest Ratio / Days to CoveriBio has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in iBio has recently decreased by 20.90%, indicating that investor sentiment is improving significantly. News and Social Media0.6 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for iBio this week, compared to 0 articles on an average week.Search Interest10 people have searched for IBIO on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, iBio insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.12% of the stock of iBio is held by insiders.Percentage Held by InstitutionsOnly 7.90% of the stock of iBio is held by institutions.Read more about iBio's insider trading history. Receive IBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for iBio and its competitors with MarketBeat's FREE daily newsletter. Email Address IBIO Stock News HeadlinesiBio announces data from non-human primate PK study of IBIO-600April 8, 2025 | markets.businessinsider.comiBio to transfer listing to Nasdaq from NYSEFebruary 19, 2025 | markets.businessinsider.comDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retirement" process . This fired the starting gun on the biggest economic transformation in American history.April 26, 2025 | Altimetry (Ad)iBio, Inc.: iBio Reports Fiscal Second Quarter 2025 Financial ResultsFebruary 11, 2025 | finanznachrichten.deiBio, Inc.: iBio Discovers Novel Antibody Targeting Activin E in Collaboration with AstralBioJanuary 7, 2025 | finanznachrichten.deIBio Expands Cardiometabolic And Obesity ProgramJanuary 2, 2025 | markets.businessinsider.comEarnings week ahead: DIS, BABA, JD, CSCO, HD, OXY, SU, SHOP, AMAT, SPOT, and moreNovember 10, 2024 | msn.comJudge dismisses family lawsuit against Dept. of Defense after 24-year-old’s “vaccine-related” deathSeptember 27, 2024 | yahoo.comSee More Headlines IBIO Stock Analysis - Frequently Asked Questions How have IBIO shares performed this year? iBio's stock was trading at $2.42 on January 1st, 2025. Since then, IBIO stock has decreased by 62.0% and is now trading at $0.9190. View the best growth stocks for 2025 here. How do I buy shares of iBio? Shares of IBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of iBio own? Based on aggregate information from My MarketBeat watchlists, some other companies that iBio investors own include Mesoblast (MESO), Mobileye Global (MBLY), KULR Technology Group (KULR), IonQ (IONQ), Guardforce AI (GFAI), Fastly (FSLY) and Exscientia (EXAI). Company Calendar Today4/26/2025Next Earnings (Estimated)5/12/2025Fiscal Year End6/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry Biotechnology Sub-IndustryPharmaceutical Products Current SymbolNYSEAMERICAN:IBIO CIK1420720 Webwww.ibioinc.com Phone302-355-0650Fax302-356-1173Employees100Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-65,010,000.00 Net MarginsN/A Pretax Margin-41,546.00% Return on Equity-150.59% Return on Assets-52.83% Debt Debt-to-Equity Ratio0.04 Current Ratio0.91 Quick Ratio0.91 Sales & Book Value Annual Sales$2.38 million Price / Sales1.34 Cash FlowN/A Price / Cash FlowN/A Book Value$15.15 per share Price / Book0.06Miscellaneous Outstanding Shares3,480,000Free Float3,445,000Market Cap$3.20 million OptionableN/A Beta-3.77 A Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free Report This page (NYSEAMERICAN:IBIO) was last updated on 4/26/2025 by MarketBeat.com Staff From Our PartnersTrump’s tariffs just split the AI market in twoTrump’s tariff just split the AI market – among others – in two. One group of AI companies—the ones relying...Traders Agency | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredIt’s absolute chaos in Silicon Valley right now…If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | SponsoredTrump’s treachery Forget what the media tells you. Trump’s inner circle may be pushing a financial reset that mirrors moves from...Porter & Company | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share iBio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.